CEP72‐ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next‐generation sequencing

ROS1 rearrangement is a validated therapeutic driver gene in non‐small cell lung cancer (NSCLC) and represents a small subset (1–2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi‐targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, You‐cai, Zhou, Yue‐fen, Wang, Wen‐xian, Xu, Chun‐wei, Zhuang, Wu, Du, Kai‐qi, Chen, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928353/
https://www.ncbi.nlm.nih.gov/pubmed/29517860
http://dx.doi.org/10.1111/1759-7714.12617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928353/
https://www.ncbi.nlm.nih.gov/pubmed/29517860
http://dx.doi.org/10.1111/1759-7714.12617

Ejemplares similares